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ABSTRACT
Objective: The aim of this study was to evaluate and compare the efficacy of punch biopsies and
cervical scrapes in the detection of human papillomavirus (HPV) DNA from the cervix and com-
pare the results with the histopathologic diagnosis.
Methods: The specimens were collected simultaneously, and HPV DNA was detected using a
liquid hybridization test.
Results: Biopsies and scrapes were equally efficient, but each detected only two-thirds of all
HPV-DNA-positive patients. Thus, the positivity rate increasedwhen both tests were used. Overall,
13% ofpatients with normal histopathology, 38% of patients with benign atypia, and 66% ofpatients
with squamous intraepithelial lesions (SIL) were HPV-DNA positive. HPV-DNA 16 was found in
54% of HPV-DNA-positive patients with SIL, in 20% of HPV-DNA-positive patients with atypia,
and in none of patients with normal histopathology.
Conclusions: The liquid hybridization test used in this study detectsHPVDNA equally efficiently
from both biopsies and scrapes. The test can be performed in I working day. However, the sensitiv-
ity of the test is low, and it only detects a limited number ofHPV types. (C) 1994 Wiley-Liss, Inc.
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nfection with specific types of human papilloma-
virus (HPV) is associated with different types of
cervical lesions. Therefore, HPV typing has be-
come increasingly important.
1-4 Many techniques
are currently available for HPV typing. 3’s-7 Sand-
wich hybridization in liquid phase is a rapid typing
technique with a comparable sensitivity and speci-
ficity to the more commonly used dot blot tech-
nique.
8-1 Cervical scrapes have been predomi-
nantly used in previous studies of commercially
available HPV-DNA test kits. 3’8-1 Only a few
studies have compared cervical scrapes and cervical
biopsies in the detection of I-IPV DNA. 2’3 How-
ever, since patients with even mild degrees of cyto-
logic atypia will be usually evaluated by colposcopy
and directed biopsy, 4’15 it would be meaningful to
also use the biopsy material for HPV typing.
In this study, we used a commercially available
liquid hybridization test that allows detection and
typing of HPV-DNA types 6/11, 18/33, 16, and
31. We compared the I-IPV-DNA typing results
from cervical scrapes and cervical biopsies collected
simultaneously from patients with cytologic atypia
referred for colposcopy.
Address correspondence/reprint requests to Dr. Pekka Nieminen, Department of Obstetrics and Gynecology, University
Hospital, Haartmaninkatu 2, 00290 Helsinki, Finland.
Clinical Study
Received March I, 1994
Accepted June 23, 1994DETECTION OF HPV DNA IN CERVICAL BIOPSIES NIEMINEN ET AL.
SUBJECTS AND METHODS
The study population consisted of 202 patients with
cytologic atypia referred for colposcopy. The rea-
son for referral was dyskaryotic cytologic changes
consistent with low- or high-grade squamous in-
traepithelial lesions (SIL) in 119 cases, atypical
squamous cells of undetermined significance in 72
cases, glandular-cell atypia in 8 cases, and other
inflammatory changes in 3 cases.
Collection of Specimens
During each patient’s speculum examination, a cel-
lular-scrape specimen for HPV-DNA testing was
collected using the AffiProbe HPV specimen col-
lection kit (Orion Corporation, Orion Pharmaceu-
tica, Helsinki). A colposcopy was next performed.
The Olympus OCS colposcope (Olympus Optical
Co. Ltd., Tokyo, Japan) or Zeiss colposcope (Zeiss
AG, Germany) was used throughout the study.
Standard terminology was used to describe colpo-
scopic findings.
16 Colposcopically directed biop-
sies were obtained from the most representative
areas of the atypical transformation zone of the
cervix. Parallel sections of biopsy specimens ob-
tained from each lesion were used for routine histo-
pathologic examination and HPV-DNA testing.
The scrape specimens were processed during the
same day. Cells were recovered from the sample
medium after centrifugation for 5 min at 2,000
rpm. The cells in approximately 150 p,1 of the
sample medium were frozen at -20C until tested
by the AffiProbe HPV-DNA test kit. The biopsy
specimens were kept frozen in the sample medium
of the AffiProbe biopsy collection kit until tested.
Cervical biopsies were pretreated with proteinase K
digestion overnight at 37C to release the viral
DNA.
HPV-DNA Testing
The adequacy of the specimens was verified by the
AffiProbe HPV-Specimen Adequacy test kit (Orion
Corporation, Orion Pharmaceutica).
17 The Af-
fiProb HPV-DNA test kit allows simultaneous
detection and typing of HPV-DNA 6/11, 18/33,
16, and 31. It is based on sandwich hybridization
in solution followed by affinity-based hybrid col-
lection (Orion Corporation, Orion Pharmaceu-
tica).
0 The specimens were first divided in 4 3 0-1xl
aliquots, each of which was treated separately with
specimen pretreatment solution to denature the vi-
TABLE I. Comparison of cervical scrape and biopsy
in the detection of HPV DNA by AffiProbe test
Biopsy
Scrape Positive Negative Total
Positive 24 30 54
Negative 26 122 148
Total 50 152 202
ral DNA. The aliquots were next subjected to hy-
bridization in solution for 3 h with type-specific
DNA-detector probes labeled with 3Ss isotope and
biotinylated capture DNA probes. The formed hy-
brids were subsequently collected onto streptavi-
din-coated microtiter plates and washed, and the
eluted detector probes were counted in a liquid
scintillation counter. The cutoff of the test was set
according to the mean of 2 low-positive standards
included in the kit. 8,10 In all cases, the cutoffwas at
least 1.5 times the mean of the background. The
specimens were considered positive if the ratio of
the signal to the cutoff obtained was > 1. Since the
AffiProbe HPV-DNA test shows cross-reaction for
HPV types 16 and 31 if more than 10
7 molecules
are present, the following rules, based on experi-
mentg with cloned HPV DNAs, were adapted to
rule out cross-reactions. If the signal-to-cutoff ratio
for of the types was higher than 10 and for the
other type between and 3, the latter finding was
considered the cross-reaction. If the signal-to-cut-
off ratio was lower than 10 for both types, the
specimen was considered positive for both types.
RESULTS
Satisfactory cervical scrapes and cervical biopsies
were obtained from 202 patients, of whom 80
(40%) were positive for HPV-DNA 6/11, 18/33,
16, or 31 by cervical scrape or biopsy and 122 were
negative for HPV DNA by both specimens.
Of the 80 HPV-DNA-positive patients, cervi-
cal scrape alone detected 54 (67.5%) and cervical
biopsy alone detected 50 (62.5%) (Table 1). The
performance of the cervical scrape or biopsy in the
detection of specific HPV-DNA types is shown in
Table 2. HPV-DNA 16 was found 2 times more
often in cervical scrapes than in cervical biopsies.
Other I-IPV-DNA types were found to be equally
common in both types of specimens.
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TABLE 2. Number of positive specimens by
HPV-DNA type
HPV-DNA type
Positive specimen 6/I 18/33 16 31
Scrape (N 54) 10 19 25 12
Biopsy (N 50) 13 19 13 12
aThirteen patients had > HPV-DNA types.
bSix patients had >1 HPV-DNA types.
TABLE 3. Histopathologic findings in relation to
HPV-DNA positivity from cervical scrape or biopsy
HPV-DNA positive
Histopathologic Biopsy
finding Biopsy Scrape or scrape
Normal (N 2 I) 2 2 3 (I 3%)
Atypia (N 152) 35 34 58 (38%)
SIL (N 29) 13 14 19 (66%)
aHP-DNA 6/I I, 18/33, 16 or 3 I.
TABLE 4. Correlation of histopathology and
detection of specific HPV-DNA types in biopsies
HP-DNA type in biopsy
Histopathology 6/I 18/33 16 31 Mixed
Normal (N 21) 0 0 0
Atypia (N 152) 10 12 5 3 5
SIL (N 29) 2 6 3
Two had HP-DNA 6/11 and 18/33, 2 had HP-DNA 16 and 31, and
had HP-DNA 31 and 18/33.
bHPV-DNA 16, 31, and 18/33 positive.
Biopsy showed normal histopathology in 21 pa-
tients, mild atypia in 152 patients, and SIL in 29
patients. HPV DNA was detected in 3/21 (13%)
patients with normal histopathology, in 58/152
(38%) patients with atypia, and in 19/29 (66%)
patients with SIL (Table 3). As shown in Table 3,
there were no differences in the detection of HPV
DNA in the different categories of cervical lesions,
or from normal cervix whether studied from cervi-
cal scrape or biopsy.
Table 4 shows the correction between the histo-
pathologic findings and the detection of specific
HPV-DNA types in a biopsy taken from the same
lesion. HPV-DNA 16 was detected in 7/13 (54%)
HPV-DNA-positive biopsies in patients with SIL,
in 7/35 (20%) HPV-DNA-positive patients with
atypia, and in none ofthe biopsies taken from HPV-
DNA-positive patients with normal histopathology.
HPV-DNA 6/11 was detected in only (8%) pa-
tient with SIL and in 12 (34%) patients with aty-
pia. Two or more HPV-DNA types were detected
in (8%) patient with SIL and in 5 (14%) patients
with atypia.
DISCUSSION
The AffiProbe liquid hybridization test used in this
study is suitable for screening large numbers of
specimens. The test can be performed in working
day. In a previous study, we evaluated the same test
kit in the detection and typing ofHPV DNAs from
cervical and vaginal scrapes. 8’9 We found that the
sensitivity was comparable to that of a commer-
cially available dot blot test (ViraType, Digene Di-
agnostics, Beltsville, MD).
In this study, we compared the detection and
typing of HPV DNA from cervical scrapes and
colposcopically directed biopsies from patients with
normal cervix, patients with benign atypia, and
patients with SIL. Our goal was to find out whether
biopsy could also be used for HPV-DNA detection
by AffiProbe.
We found that either one of the sampling proce-
dures gave two-thirds of all positive results ob-
tained by combining both sampling procedures.
Although a cervical scrape most likely represents a
larger epithelial area than a biopsy, the overall
positivity rate by scrape alone or biopsy alone was
almost identical. It was not surprising that a biopsy
was not better than a scrape since a biopsy repre-
sents only a small area of the lesion and probably a
smaller amount of viral DNA.
We found that combining scrape and biopsy
increased the overall positivity rate of all HPV-
DNA types. Likewise, a combined scrape collected
from several genital epithelial surfaces is more rep-
resentative than any single scrape from location
only. On the other hand, cervical scrape detects
66% of all HPV-DNA 16-positive specimens,
whereas biopsy detects only 34%, suggesting that
HPV-DNA 16 infection is diffuse, affecting large
areas of the cervicovaginal mucosa.
The findings from the present study indicate
that performing both scrapes and biopsies would
increase the sensitivity. However, it would also add
to the cost and therefore cannot be recommended.
Since the scrape was more sensitive than the biopsy
in the detection of HPV-DNA 16, switching to a
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biopsy specimen for HPV testing cannot be recom-
mended either.
As shown in many previous studies, 1’4’5 there
was an increase in the overall HPV-DNA positivity
with increasing severity ofthe lesion. Furthermore,
the rate ofI-IPV-DNA 16 positivity increased from
0 in normal cervix to 54% in SIL when both HPV-
DNA testing and histopathologic examination were
performed on biopsies obtained from the same le-
sion.
One obvious problem was that the overall sensi-
tivity of" the test appeared to be quite low. It is
somewhat disturbing that fewer than half" the pa-
tients with any atypia and only two-thirds of" the
patients with histologically confirmed SIL had
HPV DNA detected by either specimen.
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